Publication
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Journal Paper/Review - May 13, 2019
Untch Michael, Hackmann John, Blohmer Jens-Uwe, Rhiem Kerstin, Schmitt Wolfgang D, Furlanetto Jenny, Gerber Bernd, Huober Jens, Nekljudova Valentina, von Minckwitz Gunter, Hanusch Claus, Just Marianne, Fasching Peter A, Jackisch Christian, Schneeweiss Andreas, Schmatloch Sabine, Aktas Bahriye, Denkert Carsten, Schem Christian, Wiebringhaus Hermann, Kümmel Sherko, Warm Mathias, Loibl Sibylle
Units
PubMed
Doi
Citation
Type
Journal
Publication Date
Issn Electronic
Pages
Brief description/objective
PURPOSE
The GeparSepto trial demonstrated that weekly nanoparticle albumin-bound (NAB)-paclitaxel significantly improves the pathologic complete remission rate compared with weekly solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide as neoadjuvant treatment in patients with primary breast cancer (BC). Here, we report data on long-term outcomes.
METHODS
Patients with histologically confirmed primary BC were randomly assigned in a 1:1 ratio to 12 times weekly NAB-paclitaxel 150 mg/m (after study amendment, 125 mg/m) or weekly sb-paclitaxel 80 mg/m followed in both arms by four times epirubicin 90 mg/m plus cyclophosphamide 600 mg/m every 3 weeks. Patients with human epidermal growth factor receptor 2 (HER2)-positive BC received dual antibody treatment with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) and pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks) concurrently to chemotherapy and continued for 1 year.
RESULTS
A total of 1,206 patients started treatment, 606 with NAB-paclitaxel and 600 with sb-paclitaxel. After a median follow-up of 49.6 months (range, 0.5 to 64.0 months), 243 invasive disease-free survival (iDFS) events were reported (143 in the sb-paclitaxel and 100 in the NAB-paclitaxel arm). At 4 years, overall patients treated with NAB-paclitaxel had a significantly better iDFS compared with sb-paclitaxel (84.0% 76.3%; hazard ratio, 0.66; 95% CI, 0.51 to 0.86; = .002), whereas overall survival did not significantly differ between the two treatment arms (89.7% 87.2%, respectively; hazard ratio, 0.82; 95% CI, 0.59 to 1.16; = .260). Long-term follow-up of the treatment-related peripheral sensory neuropathy (PSN) showed a significant decrease of the median time to resolve PSN after NAB-paclitaxel 125 mg/m compared with NAB-paclitaxel 150 mg/m.
CONCLUSION
The significantly higher pathologic complete response rate with NAB-paclitaxel translated into a significantly improved iDFS in patients with early BC as compared with sb-paclitaxel. PSN improved much faster under NAB-paclitaxel 125 mg/m compared with NAB-paclitaxel 150 mg/m.